Ideas in the lab

Drug Repurposing
with a Purpose

Your partner for accelerated growth in pharma business through exclusive and differentiated new products

We envision to be a one-stop-shop for cutting edge, first-time novel pharma products to boost the growths of our pharma partners in leaps and bounds

About Us

MedRenova is a startup conceived by pharma R&D stalwarts from India to create unparallelled, differentiated and “first-time to market” new products, that will be patented and licensed to Pharma companies. It will use a virtual eco-system created for this purpose by alliances with relevant stakeholder- R&D companies to expedite development.

Identify Unmet Medical Needs & Market Gaps

It involves recognizing diseases or conditions with limited or inadequate treatment options, presenting opportunities for new or repurposed therapies.

Medical Gadgette

Assessing Disease Burden and Patient Needs

This involves evaluating the prevalence and impact of diseases where current treatments are not optimally effective or unavailable, highlighting areas that require urgent medical advancements.

Analyzing market opportunites

Analyzing Market Opportunities and Competitor Landscape

By examining the competitive environment and identifying gaps in existing treatment offerings, companies can uncover potential markets for innovative or repurposed drugs.

Generate Many Ideas to Find One Great Idea

Explore a wide range of concepts through interdisciplinary collaboration, data analysis, and iterative testing to uncover innovative product ideas that could effectively address unmet medical needs and have the potential for successful market impact.

New ideas
Product idea machine

Analyze Existing Drug Mechanisms

Review the mechanisms of action of approved drugs, focusing on their biological pathways and potential to affect conditions beyond their original indication. Use the information on new disease targets to match the potential action of existing drugs on these new mechanisms.

Collaborate with Medical Experts

Partner with physicians, researchers, and disease experts to identify off-label uses or emerging disease trends that could benefit from existing drugs. Convert off-label regimens into legitimate treatment paradigms to conduct randomized controlled phase 3 trials for marketing authorization.

Explore Drug Combinations

Investigate how existing drugs, when combined with others, may offer synergistic effects or new therapeutic benefits in treating different diseases. Create value by changing dosage forms/ routes/ regimens that would be more beneficial than just an addition of these drugs into a fixed-dose combinations.

Team behind MedRenova

A seasoned multidisciplinary team of functional experts, supported by veteran leaders from the pharmaceutical, fintech, and IT industries who provide both strategic insight and investment, transforms ideas into projects that achieve successful market introduction

Gopakumar Subramonian

Chairman

Gopakumar Subramonian is the Chairman of MedRenova, with over three decades of leadership experience across banking, fintech, and global capability centers.

An MBA graduate from XLRI Jamshedpur (1988), he began his career with Standard Chartered Bank, working in India, the UK, and Africa across money markets and fixed income trading as well as operations leadership. In 2007, he joined Credit Suisse, where he helped scale its global capabilities from India and served on the Board of Credit Suisse India.

In 2015, Gopakumar joined Fiserv, the world’s leading fintech. He served as COO and later as SVP heading India delivery for some of Fiserv’s largest global businesses. In 2024, he was appointed CEO of Fiserv India and joined its Board, driving innovation, talent, and transformation at scale.

At MedRenova, Gopakumar brings this cross-industry expertise to healthcare. He leads the company’s mission to fuse AI/ML with strong scientific and wet-lab expertise—accelerating drug repurposing and advancing next-generation therapies.

Devesh Malladi

Director

Devesh, currently serving as the Managing Director of Embio. He is a Pharmacy graduate from Delhi University and a M.Tech in Bio-Engineering from Andhra University. In 1997, he was selected for the Chevening Scholarship for young managers, awarded by the British Government.

He started his career in the Malladi Group in projects, then R&D and as head of manufacturing operations. He started with the Company in 1995 as Vice President (Technical) and took on the role of Managing Director in 1998. He has a wide exposure to marketing, operations, finance, R&D and project management. He has been instrumental in the formulation of long term strategic plans of the company and has been a guiding force behind the growth of the company.

He also plays a key role in Policy framework in the space of Narcotic Drugs and Psychotropic Substances as the Chairman of NDPS sub-committee of Indian Drug Manufacturers Association (IDMA).

Dr. Dhananjay Bakhle

Chief Executive Officer

In a career spanning 4 decades, worked in different spheres of Medical/ Clinical/ Biotech R&D leading medical/ clinical & regulatory departments of both Indian & MNC Pharma companies in India. Started with Phase 1 studies in 1983 and retired recently after leading global clinical studies for NCEs and Biologicals for a big Pharma. He was a member of several regulatory committees in India that framed guidelines for GCP, Bioequivalence, IPR, Phase I and Ethical Marketing of Pharmaceuticals etc. Profiled in a book by Tata McGraw Hill – “Thought Leaders” amongst 22 insightful leaders in India.

Dr. Karthik Upadhya

Chief Technology Officer

Karthik has a decade-long experience in AI/ML. He received the M.Tech. degree from IIT Madras, India, in 2011 and DSc. (Tech) from Aalto University, Finland in 2018. He was a Visiting Researcher with the Wireless Networking and Communications Group, The University of Texas at Austin in 2017. His research interests include signal processing, machine learning, drug discovery and repurposing, and convex optimization.

Manjusha Joshi

Principal Technical Advisor, Specialty Formulations

With over 32 years of extensive experience in pharmaceutical research and development, she has been a seasoned leader in product development, having successfully formulated and launched more than 300 products across diverse dosage forms. Her career includes significant roles as Head of Formulations R&D at two leading organizations, where she managed teams of 120 scientists, driving innovation and ensuring successful delivery of high-quality formulations.

Dr. Kshipra Gharpure

Lead – Scientific, Regulatory & Project Management

A PhD from MD Anderson Cancer Center, Texas, USA in Ovarian Cancer Research with over 7 years of experience in research and scientific writing. Possesses a distinctive combination of scientific expertise and project management skills, seamlessly integrated to deliver exceptional results. An accomplished scientist skilled in new product evaluation with a proven track record of delivering quality publications in high-impact international journals. Extensive experience in fostering cross-functional collaborations in multidisciplinary environments.

Dr. Chitra Bargaje

Lead Consultant – Quality and Compliance (GVP/GCP)

Dr. Chitra Bargaje is a senior Quality and Compliance expert with over 24 years of global experience in GCP and Pharmacovigilance (PV). She brings a strong quality-first mindset, built through extensive leadership of GVP/GCP compliance programs, regulatory inspections, and enterprise-wide quality systems across multiple geographies. She has a proven track record of designing, streamlining, and strengthening QMS frameworks to ensure sustained inspection readiness and regulatory adherence.

At Lupin, she was instrumental in transforming clinical research and PV quality processes and later led the global PV function, driving measurable improvements in compliance maturity and operational excellence. Her approach consistently integrates robust quality governance with practical, execution-focused solutions.

She comes on board from Feb 2026.

Deepakk Didwania

Lead Consultant – Financial Planning & Transaction Support

Chartered Accountant with an all-India rank and over 25 years of experience across manufacturing, R&D, and business finance. Has led plant finance and controllership functions at Aditya Birla Fashion and Retail Limited, as well as R&D and business finance at Lupin Limited.

Expertise includes M&A and valuations, MIS, budgeting, planning and forecasting, commercial agreements, profit improvement initiatives, and strategic decision support for capex investments and third-party collaborations. Known for combining strong financial rigor with practical business insight to drive sustainable value creation.

Re-Innovating Medi-Scene

With the availability of unique customized and exclusive new products, any research based pharma company can re-innovate the medical scene in the Doctor’s clinic for their promotional efforts while providing new therapeutic solutions

Current Scenario

Huge promotional pressure on doctors with undifferentiated products which crowd the market place for same indication. Transactional nature of Dr-Pharma relationship confounds the critical factors that should ideally decide their prescriptions.

New Scenario

With an exclusive new product that will be a first in the market, we can offer unique marketing opportunities for pharmaceutical companies. This will also enable prescribers to deliver effective therapeutic solutions for diseases with unmet medical needs.


Discover a new world of possibilities

Welcome to a world of limitless possibilities, where the journey is as exhilarating as the destination, and where every project is an opportunity to make your mark on the market segment that you operate. The only limit is the extent of your imagination.

Pharma lab churning molecules

Frequently Asked Questions

This FAQ section addresses frequently asked questions to assist visitors in understanding our drug repurposing initiatives and services.

What is drug repurposing?

Drug repurposing involves identifying new therapeutic uses for existing, approved drugs that were originally developed for a different condition.

How does drug repurposing reduce development time?

Since repurposed drugs have already undergone safety testing, the development process is often faster, as the focus shifts primarily to efficacy in new indications.

What is the role of clinical trials in drug repurposing?

Randomized controlled clinical trials are essential to confirm the efficacy and safety of repurposed drugs for their new indications, ensuring that they provide therapeutic benefits for patients.

How can patients benefit from drug repurposing?

Patients can gain access to effective treatments more quickly through repurposed drugs, especially for conditions where no adequate therapies currently exist, improving their quality of care.

Are repurposed drugs as safe as newly developed drugs?

Yes, repurposed drugs have established safety profiles, which typically reduces the risk of adverse effects when used for new therapeutic purposes.

How can pharmaceutical companies or researchers collaborate with your startup?

We welcome collaborations through partnerships, co-development opportunities, or licensing agreements to advance our drug repurposing initiatives.

Contact Us

Go back

Your message has been sent

Warning
Warning
Warning
Warning
Warning.

Chennai office:
No.41, 1st Floor, Chakrapani Street, West Mambalam, Chennai,
Chennai City Corporation,
Tamil Nadu, India, 600033

Pune office:
B-1103, MyWorld,
Opposite Balewadi high street,
Baner-Balewadi road,
Pune – 411045,
Maharashtra

Bengaluru office:
No. 261, 9th Main,
Ideal Homes Township,
Rajarajeshwari Nagar,
Bengaluru 560098,
Karnataka